Stocks · News reference

NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology

Jul 15, 2026, 1:01 PMBenzinga Newsdesk

NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NCEL

Source: benzinga
Observed: Jul 15, 2026, 1:01 PM
Checked: Jul 15, 2026, 1:01 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 14, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
Read original at benzinga
AKAN BYSI CAPR CBUS ETON
BenzingaJul 31, 2026, 1:01 PMBenzinga Newsdesk
NewcelX Announces Private Placement Of 347,134 Shares At $4.033 Per Share
Read original at benzinga
NCEL
BenzingaJul 13, 2026, 11:28 AMBenzinga Newsdesk
Laidlaw & Co. Initiates Coverage On NewcelX with Buy Rating, Announces Price Target of $23
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating and announces Price Target of $23.
Read original at benzinga
NCEL

NewcelX Issued Patent From Brazilian Patent And Trademark Office For Its Nnovative Cell Selection And Enrichment Technology

Connected markets

Related headlines

12 Health Care Stocks Moving In Friday's Pre-Market Session

NewcelX Announces Private Placement Of 347,134 Shares At $4.033 Per Share

Laidlaw & Co. Initiates Coverage On NewcelX with Buy Rating, Announces Price Target of $23